◈ Nootpedia
Compact view
Research pass: medium Peptide · Injectable SKIP-FOR-NOW MEDIUM

GHRP-2

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

For Dylan at 20 — same core "no marginal benefit at peak natural GH/IGF-1 axis" rationale as ipamorelin/CJC-1295, plus an additional layer: GHRP-2's cortisol + prolactin spillover is a categorical disadvantage versus the cleaner selective GHRP (ipamorelin) for any user who would actually consider this class. The hierarchy is: in young healthy users, no GHRP needed; in users where one is appropriate, ipamorelin replaces GHRP-2 on every dimension except raw GH-pulse magnitude (which is rarely the limiting factor). MEDIUM rather than HIGH because the 30+ longevity-clinic context where some operators still prefer GHRP-2's stronger pulse is genuine — not relevant for Dylan but the compound has a non-zero use case. Verdict moves to SKIP-PERMANENT only if Dylan stays untested-amateur indefinitely with no career path involving sanctioned testing AND we confirm ipamorelin dominates on his future use cases (which it does on first principles).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, healthy with peak natural GH/IGF-1 (Dylan-archetype)
    SKIP-AT-

    (MEDIUM confidence). Endogenous GH/IGF-1 is at peak; pulsatile GH amplification adds marginal benefit at the cost of WADA exposure (irrelevant to Dylan), cortisol/prolactin spillover, glucose modulation, and somatotroph + HPA axis perturbation in a system that doesn't need it. Same core logic as CJC-1295 and ipamorelin, with the additional reason that even within the GHRP class, ipamorelin dominates GHRP-2 on cleanliness for any user who would actually consider this intervention. Behavioral GH levers (deep sleep, training, intermittent fasting, low evening glucose) are free and more impactful.

  • 20-30 with documented secondary GH deficiency
    NOT FIRST LINE

    Recombinant GH or specialist-prescribed alternative is appropriate. GHRP-2 has a Japanese diagnostic-approval role here (single-dose challenge) but not a chronic treatment role.

  • 30-50, executive maintenance, normal IGF-1
    SKIP-FOR-NOW

    prophylactically; if a GHRP enters consideration at all, ipamorelin replaces GHRP-2 for cleaner profile.

  • 30-50 with measurably declining IGF-1 + recovery + sleep architecture
    OPTIONAL-ADD

    as part of the GHRP class — but ipamorelin is the preferred member of the class. GHRP-2 retains a use case only for users who specifically want the larger raw GH pulse and accept the spillover.

  • 50+ general longevity / anti-aging
    OPTIONAL-ADD

    in clinic-supervised contexts; tesamorelin and ipamorelin/CJC are preferred. GHRP-2 is largely deprecated in 2026 longevity-clinic practice.

  • Anxiety-prone
    AVOID

    The cortisol/prolactin spillover is a bad fit for anxiety-prone users; ipamorelin replaces it cleanly here.

  • Tested athlete (WADA, USADA, NCAA, professional combat sport)
    SKIP-PERMANENT

    S2-banned, detectable in urine.

  • DylanHigh athletic load, untested status (Dylan profile)
    SKIP-AT-

    No measurable benefit at peak natural baseline; address sleep + training load + nutrition first.

  • Sleep-disordered
    A

    sleep architecture directly. Ipamorelin amplifies natural N3 GH pulses with less HPA disruption; if a GHRP is appropriate, ipamorelin replaces GHRP-2.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    in adult populations 30+ in supervised contexts, but ipamorelin preferred. BPC-157/TB-500 are more direct injury-recovery peptides.

  • Strength/anabolic-focused
    MARGINAL

    Effects are modest; not a true anabolic peptide. The marginal raw-GH-pulse advantage over ipamorelin doesn't translate cleanly to body-comp gains beyond what ipamorelin produces, and the spillover complicates training-recovery feel.

  • Diagnostic GH-deficiency challenge
    APPROVED

    USE (Japan). Single-dose 100 mcg IV is the validated diagnostic protocol; GHRP-2 is the right tool for this single application.

▸ Subjective experience (deep)

What users report (compiled from peptide forums, longevity Twitter, clinic patient reports 2018-2026, with the bias caveat that reports are now largely retrospective from users who switched to ipamorelin):

Acute (first hour post-injection):

  • Hunger surge within 15-30 min — meaningful, especially fasted; easily noticeable. Less than GHRP-6 but materially more than ipamorelin.
  • Mild flush / warmth in face and neck (~15-30 min, transient)
  • Some users report a faint "anxious/wired" feel — likely attributable to cortisol/ACTH spillover; absent on ipamorelin
  • Mild light-headedness or slight nausea in a minority

First 1-2 weeks of chronic use:

  • Sleep deepening (similar to ipamorelin) — slow-wave sleep enhancement is the most consistent positive effect
  • Some users report waking less rested than expected (cortisol elevation theory)
  • Mild water retention, similar to ipamorelin
  • Mild headache (first few injections most common)

Weeks 2-8:

  • Body-comp shifts similar in magnitude to ipamorelin (modest fat loss, modest lean gain at 8-12 weeks) — reports of slightly larger effect than ipamorelin at equivalent doses, consistent with the larger GH pulse
  • Lethargy / "blunted" feel more reported than with ipamorelin — attributable to chronic mild cortisol elevation
  • Appetite remains noticeably elevated throughout use — for users trying to recomp / cut, this is a meaningful disadvantage; for users trying to bulk, it's a feature

Compared to ipamorelin:

  • Larger raw GH pulse, ~20-50% bigger at matched dose — measurable on bloodwork, sometimes felt subjectively as more "muscle fullness" / pump
  • Worse "feel" overall (cortisol/prolactin spillover) — users often describe ipamorelin as "cleaner / nicer" even though body-comp results are similar
  • Stronger appetite drive — relevant for combat athletes managing weight
  • More water retention reported in some users (possibly aldosterone-mediated)

Compared to GHRP-6: Smaller appetite surge, smaller cortisol spillover, modestly smaller prolactin spillover. GHRP-2 is the "less dirty" of the two non-selective compounds but still meaningfully dirtier than ipamorelin.

Compared to MK-677: GHRP-2 produces transient pulsatile GH (~2h pulse, clears); MK-677 produces sustained 24h elevation. MK-677 brings stronger water retention, stronger appetite, larger glucose/insulin disturbance. GHRP-2 is intermediate between pulsatile-clean (ipamorelin) and tonic-dirty (MK-677).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Pulsatile dosing helps but GHRP-2's non-selective receptor activation (GHS-R1a + cross-activation at HPA axis + lactotrophs) creates more desensitization surface than ipamorelin. Users report "blunted feel" emerging in some cases at 8-12 weeks of continuous use.
  • Recommended cycle: 8-12 weeks on / 4 weeks off is the most defensible default. 5 days on / 2 days off is acceptable as a continuous-light protocol. Continuous dosing >12 weeks not recommended given the broader receptor desensitization profile relative to ipamorelin.
  • Reset protocol if needed: 4-8 weeks washout. The somatotroph axis is not chronically suppressed during use (unlike exogenous GH itself, which suppresses endogenous GH via IGF-1 feedback) — so withdrawal is not abrupt. Cortisol axis usually re-normalizes within 2-4 weeks post-discontinuation.
▸ Stacking deep dive

Synergistic with

  • CJC-1295 (no DAC, "Mod GRF 1-29") or CJC-1295 with DAC: The historical canonical pairing pre-2018. GHRH analog + GHS-R1a agonist on different pathways → larger and more synchronized GH pulse than either alone. Modern preference (2020+) shifts toward CJC-1295/ipamorelin for the same mechanism with cleaner side-effect profile.
  • Tesamorelin (FDA-approved GHRH analog, longer half-life): Same logic; tesamorelin has stronger evidence base (HIV lipodystrophy approval).
  • Sermorelin (older GHRH analog): Same pathway; shorter half-life.
  • BPC-157 / TB-500 (peptide recovery stack): Mechanistically separate; combined for systemic recovery in injury-rehab contexts.

Avoid stacking with

  • Ipamorelin: Same receptor (GHS-R1a). Adding ipamorelin to GHRP-2 is redundant; ipamorelin replaces GHRP-2 on every dimension that matters except raw pulse magnitude. Choose one — and the choice is almost always ipamorelin in 2026.
  • GHRP-6 or hexarelin: Same non-selective receptor profile; cumulatively dirtier.
  • MK-677 (ibutamoren): Both target the GHS-R1a axis. MK-677 produces tonic chronic agonism; adding GHRP-2 pulses on top is redundant and pushes total GH/IGF-1 + cortisol/prolactin exposure into supraphysiologic territory.
  • Recombinant human GH (somatropin): Direct exogenous GH suppresses endogenous pulsatile release via IGF-1 feedback, making GHRP-2's pulsatile mechanism less useful.
  • Other prolactin-elevating compounds (haloperidol, risperidone, metoclopramide, certain SSRIs in susceptible users) — additive prolactin elevation has clinical consequences in some users.
  • Glucocorticoids / chronic prednisone: Steroid-induced HPA suppression + GHRP-2 cortisol spillover compound in unpredictable directions.

Neutral / safe co-administration

  • Most non-hormonal nootropics in Dylan's stack: modafinil, bromantane, citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin — no GH-axis collision.
  • Caffeine — no interaction (caffeine itself is mildly cortisol-elevating; co-administration may amplify cortisol spillover modestly — flag for caffeine-sensitive users).
  • Creatine — no interaction; may synergize for body composition with combined GH-axis + resistance training.
  • Vitamin D3, K2 — no interaction.
▸ Drug interactions deep dive
  • Glucocorticoids (prednisone, dexamethasone): Additive on cortisol axis disruption; chronic glucocorticoid use also blunts GH/IGF-1 axis output and may reduce GHRP-2 GH response.
  • Insulin / sulfonylureas / GLP-1 agonists: GH opposes insulin action; pulsatile GH + cortisol spillover may transiently raise glucose. Monitor in diabetic / pre-diabetic users.
  • Thyroid hormone (levothyroxine): GH may increase peripheral T4→T3 conversion; in hypothyroid patients on replacement, watch for shifts in TSH/fT4 over months of use.
  • Estrogen (oral) / SERMs: Oral estrogen reduces hepatic IGF-1 production in response to GH — may blunt GHRP-2's downstream effect. Transdermal estrogen does not.
  • Prolactin-elevating medications: Additive prolactin elevation — relevant for users on antipsychotics, certain antidepressants, metoclopramide.
  • No CYP-mediated interactions (peptide; not metabolized through hepatic CYP enzymes — eliminated via peptidase degradation).
▸ Pharmacogenomics
  • GHSR (ghrelin receptor) polymorphisms: Variants in GHSR (e.g., Leu90Val, c.214C>A) modulate receptor function; some carriers have higher baseline ghrelin response and may show different GHRP-2 pharmacodynamic response. Not clinically tested for dosing.
  • GH1 / GHR polymorphisms: GHR exon-3 deletion (d3-GHR) is associated with greater IGF-1 response to GH stimulation. Carriers may experience larger downstream effects from GHRP-2.
  • IGF1 / IGFBP3 polymorphisms: Modulate IGF-1 bioavailability; affect downstream effects of any GH-axis intervention.
  • MC2R / NR3C1 (cortisol axis): Theoretically relevant given GHRP-2's cortisol spillover — variants affecting glucocorticoid receptor sensitivity could plausibly modulate the subjective "cortisol feel" of GHRP-2 vs. ipamorelin. Not clinically tested.
  • Practical note: No clinical genetic test is currently used to dose GHRP-2. Dylan's 23andMe (June 2026) will not directly report GHSR variants.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-peptide vendor (US-based) Limitless Life, Modern Aminos, CCC (Core Capsule Corp), Peptide Sciences ~$30-50 / 5 mg vial medium-high Standard gray-market lyophilized peptide; "for research use only"; verify COA + HPLC purity ≥98%
Research-peptide vendor (US-based) Core Peptides, Biotech Peptides, Pure Health Peptides ~$25-50 / 5 mg vial medium Variable reliability; check for COA + third-party testing
Pre-blended CJC-1295 + GHRP-2 Various peptide vendors ~$50-150 / 10 mg blend vial medium Convenience; lose ability to tune doses independently
Compounding pharmacy + telehealth Rx Limited (post-PCAC peptide regulatory environment 2024-2026 has narrowed compounding access for many GHRPs) $200-400/mo if available high (legit Rx) GHRP-2 compounding access has narrowed alongside CJC-1295 in the PCAC peptide review. Check current status.
Japan (Pralmorelin / KP-102D, on-label diagnostic) Kaken Pharmaceutical n/a outside Japan n/a On-label single-dose diagnostic only; not a chronic-use sourcing path.
International / Chinese / Russian peptide vendors Various $15-30 / 5 mg vial low-medium API quality variable; counterfeit risk; long shipping

Practical estimate for self-supply: ~$30-50 per 5 mg vial. At 200 mcg/day, a 5 mg vial = 25 days supply; ~3 vials/month = $90-150/month. Pre-blended CJC/GHRP-2 combos at $50-150 per 10 mg vial cover ~25-30 days. Comparable to ipamorelin at modestly lower per-vial cost (GHRP-2 is the older / more commodity peptide; ipamorelin commands a small premium).

Dylan's sourcing situation: Solvable via gray-market research-peptide vendors with COA verification. Sourcing is not the gating factor — appropriateness for him at 20 is, and the answer is not.

▸ Biomarkers to track (deep)
  • Baseline (before starting): IGF-1, IGFBP-3, fasting glucose, fasting insulin, HbA1c, AM cortisol, prolactin, ACTH (GHRP-2-specific watch markers vs. ipamorelin), TSH/fT4, lipid panel, CBC w/ hematocrit, total testosterone (HPG reference). For Dylan: he gets June 2026 baseline regardless — that's the gating step before considering any GH-axis peptide.
  • During use: IGF-1 + fasting glucose + HbA1c at week 8-12 + every 6 months. AM cortisol + prolactin + ACTH at week 4 and week 12 to characterize whether spillover is producing measurable axis disruption. Sleep tracking (Oura/Apple Watch/ring) for N3 sleep duration changes and morning HRV (cortisol-axis stress signal).
  • Post-cycle (if cycled): IGF-1 + AM cortisol + prolactin at 4 weeks post-stop to confirm return-to-baseline. Cortisol axis is the GHRP-2-specific re-normalization to verify (not relevant for ipamorelin).
▸ Controversies / open debates Live debate

1. Is GHRP-2's larger GH pulse worth the spillover?

The argument for GHRP-2: Bigger GH pulse → potentially larger downstream IGF-1 response, larger body-comp effect, larger recovery effect. Some longevity-clinic operators pre-2018 preferred this trade-off.

The argument against: The downstream IGF-1 differential between GHRP-2 and ipamorelin is small (most of the difference at the somatotroph is buffered by the IGF-1 negative-feedback loop and IGFBP saturation kinetics). The body-comp differential in chronic use is anecdotally small. Meanwhile the cortisol/prolactin spillover is a categorical disadvantage — measurable on bloodwork, felt subjectively, with downstream metabolic and HPA-axis consequences.

My read: the 2018-2026 community migration to ipamorelin reflects accurate cost-benefit accounting. GHRP-2 retains historical use and a single approved diagnostic indication, but for chronic anabolic/recovery use, ipamorelin is the strictly-better tool in nearly all scenarios. The "stronger pulse" framing is real but rarely rate-limiting; the spillover is real and almost always counterproductive.

2. The Japanese diagnostic approval — does it mean anything for chronic use?

The 2007 Pralmorelin (KP-102D) approval in Japan is specific to single-dose IV diagnostic challenge for adult-onset GH deficiency. It is rigorous evidence for that one indication and contributes essentially nothing to the chronic-use case. The chronic-use community sometimes cites the Japanese approval as if it endorsed broader use — it does not. It's evidence GHRP-2 reliably and acutely raises GH in adults, which was already mechanistically known.

3. Cortisol spillover at low chronic doses — clinically meaningful?

The cortisol/prolactin spillover characterized in the original 1990s studies was at acute high-dose challenges (100 mcg IV). At chronic 100-200 mcg SC pulsatile dosing, the spillover is smaller in magnitude per pulse but occurs 1-3× daily for weeks. Whether the cumulative HPA-axis impact is clinically meaningful is not rigorously characterized. Bloodwork at week 4 / week 12 is the empirical answer for any individual user.

4. Combat sports + appetite drive — does GHRP-2 help or hurt weight management?

For combat athletes managing weight cuts, GHRP-2's appetite drive is a meaningful operational disadvantage relative to ipamorelin. For users in surplus / building phase, it's a feature. For Dylan in active MMA training: the appetite drive is at best neutral (he hits protein goal already, doesn't need ghrelin amplification) and potentially counterproductive during weight-management phases. Ipamorelin is the cleaner choice on this dimension specifically.

5. WADA detectability and athlete risk

GHRP-2 (Pralmorelin) is detectable in urine for several weeks post-administration via LC-MS/MS testing. WADA S2 ban is in/out of competition. Irrelevant for Dylan currently (untested status) but flagged for any future career path involving sanctioned testing.

▸ Verdict change log
  • 2026-05-04 (Encyclopedia v5) — SKIP-AT-20 listed in anabolic / GH-axis peptide skip-list with note "non-selective GHRP, ipamorelin is the cleaner replacement."
  • 2026-05-06 (this file) — SKIP-AT-20 MEDIUM confidence. Verdict consistent with the broader GH-axis peptide skip-at-20 family logic for Dylan (CJC-1295, ipamorelin same direction). Additional layer: even within the GHRP class, GHRP-2 is dominated by ipamorelin on cleanliness (no cortisol/prolactin spillover), with only a marginal raw-GH-pulse advantage that is rarely rate-limiting for the use cases that actually matter. Verdict moves to OPTIONAL-ADD only at 30+ with declining recovery, sleep architecture changes, or documented sub-optimal IGF-1 — and even then, ipamorelin would be the preferred member of the class. Effectively, GHRP-2 has no plausible Dylan-specific use case at any future age unless ipamorelin specifically fails for him (no known mechanism for this).
▸ Open questions / gaps Open
  • Long-term (>1 year) safety in healthy adults using chronic GHRP-2: No published RCT data. Telehealth-clinic registries exist but are not peer-reviewed.
  • Chronic cortisol/prolactin axis sequelae: The cumulative HPA-axis impact of 1-3× daily mild cortisol pulses for months is uncharacterized. Could be negligible (axis adapts) or could matter (sustained subclinical hypercortisolism). Bloodwork-driven assessment is the only honest answer.
  • Body composition / recovery / sleep efficacy in healthy adults vs. placebo: Same gap as ipamorelin — no rigorous RCT in non-deficient adults.
  • Glucose / insulin trajectory at chronic dosing: Pulsatile dosing should be lower-impact than MK-677, but cortisol spillover compounds metabolic risk relative to ipamorelin.
  • Cancer risk from chronic IGF-1 elevation: Theoretical; same as broader GH-axis class.
  • GHRP-2 vs. ipamorelin head-to-head at modern chronic doses: No published direct comparative RCT. Community consensus that ipamorelin is the better tool is strong but not RCT-validated.
  • Whether selectivity actually matters at 100-200 mcg pulsatile dosing: Most spillover characterization was at 100 mcg IV diagnostic doses. At chronic 100-200 mcg SC, the magnitude differential between GHRP-2 and ipamorelin may be less stark than the original literature suggests — but the direction is unambiguous.
▸ Sources (full, with our context)
Back to compact view